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OBJECTIVES: New bone formation is one of the hallmark characteristics of ankylosing spondylitis, which is
thereby associated with syndesmophytes. Fetuin-A is a molecule that is abundantly found in calcified tissues
and it shows high affinity for calcium phosphate minerals and related compounds. Considering the role of
fetuin-A in the regulation of calcified matrix metabolism, we compared the fetuin-A levels in ankylosing
spondylitis patients with syndesmophytes with those in patients without syndesmophytes and in healthy
controls. We also studied other biomarkers that are thought to be related to syndesmophytes.
METHODS: Ninety-four patients (49 patients without syndesmophytes, 67.3% male, 40.7¡8.7 years; 45 patients
with syndesmophytes, 71.1% M, 43.9¡9.9 years) and 68 healthy controls (44.2¡10.6 years and 70.6% male)
were included in this study. Syndesmophytes were assessed on the lateral radiographs of the cervical and
lumbar spine. The serum levels of fetuin-A, dickkopf-1, sclerostin, IL-6, high-sensitivity C-reactive protein and
bone morphogenetic protein-7 were measured with an enzyme-linked immunosorbent assay.
RESULTS: Patients with syndesmophytes had significantly higher levels of fetuin-A compared with patients
without syndesmophytes and controls (1.16¡0.13, 1.05¡0.09 and 1.08¡0.13 mg/ml, respectively). However,
fetuin-A was not different between the patients without syndesmophytes and controls. Bone morphogenetic
protein-7 was significantly lower; dickkopf-1 was significantly higher in patients with ankylosing spondylitis
compared with controls. The sclerostin concentrations were not different between the groups. In regression
analysis, fetuin-A was an independent, significant predictor of syndesmophytes.
CONCLUSION: Our results suggest that fetuin-A may a role in the pathogenesis of bony proliferation in
ankylosing spondylitis.
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& INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory
disorder that mainly affects the sacroiliac joints and lumbar
spine. New bone formation is one of the hallmark
characteristics of the disease, which is thereby associated
with syndesmophytes and ankylosis (1). Structural damage
in the spine is associated with reduced spinal mobility and
disability and conventional X-rays of the spine are used for
the standard assessment of these changes (2,3). In recent
years, there has been considerable interest in the prediction
and pathogenesis of syndesmophyte formation. Therefore,
several studies have been conducted to identify the factors
affecting this process. Today, biomarkers have become a
very important field of research in spondyloarthropathy. In
this regard, various biomarkers have been used to under-
stand the underlying factors responsible for syndesmophyte
formation. However, available data on this subject are still
limited and additional information is required to clarify the
underlying mechanisms of new bone formation in AS. In a
recent study, we reported increased serum fetuin-A levels
compared with controls (4). Considering the role of fetuin-A
in the regulation of calcified matrix metabolism (5), we
designed this study with the primary objective of compar-
ing the fetuin-A levels in AS patients with and without
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syndesmophytes versus healthy controls. Additionally, we
studied other biomarkers that are suggested to be related to
the development of syndesmophytes in AS patients.
& METHODS
Study population and clinical assessment
The sample size was calculated with the results of
previous studies that investigated the levels of fetuin-A
(4), dickkopf-1 (DKK-1) (6) and bone morphogenetic
protein-7 (BMP-7) (7) based on a= 0.05 and a power of
80%. At least 39 patients were required per group. We
excluded subjects with renal impairment (serum creatini-
ne.1.4 mg/dl) and patients who were treated with gluco-
corticoids during the previous four weeks. We
consecutively enrolled 45 AS patients with syndesmophytes
and 49 AS patients without syndesmophytes. All patients
met the 1984 modified New York criteria for AS (8). To
assess the disease activity, functional ability and spinal
mobility, we used the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) (9), Functional Index (BASFI) (10)
and Metrology Index (BASMI) (11), respectively. There were
68 healthy subjects who served as a control group. The
controls were the relatives of the health professionals and
blood donors without inflammatory back pain. Data
regarding cardiovascular risk factors, such as smoking
status (defined as ever/never smokers), hypertension (HT)
and diabetes mellitus (DM) were collected. The symptom
duration and past or current treatment for AS were also
recorded. Local ethical committee approval was obtained
and all patients signed informed consent forms.
Radiological evaluations
Lateral plain radiographs of the cervical and lumbar spine
were used to detect syndesmophytes. The anterior sites of the
lower and upper portion of each vertebra were randomly and
blindly assessed by two experienced rheumatologists. In
discordant cases, radiographs were re-evaluated by both
readers together and consensus was reached. The overall
kappa value for the inter-examiner agreement for the
presence/absence of syndesmophytes was 0.706. The intra-
rater agreement for observers 1 and 2 were 0.77 and 0.85,
respectively.
Laboratory measurements
Following an overnight fast, venous blood samples for
laboratory tests were collected between 8:00 and 9:00 AM.
Serum samples were preserved at 280 C˚ until assayed. The
following enzyme-linked immunosorbent assay (ELISA)
kits were applied according to the manufacturers’ instruc-
tions:
High-sensitivity C-reactive protein (hs-CRP; BioCheck,
USA, Cat No: BC-1119): The sensitivity of hs-CRP was
0.1 mg/L. The intra-assay and inter-assay coefficients of
variation were 4.44% and 3.28%, respectively.
Interleukin-6 (IL-6; Assay Pro, USA, Cat No: EI1006-1):
The minimum detectable dose of IL-6 is ,0.008 ng/ml. The
intra-assay and inter-assay coefficients of variation were
4.9% and 7.5%, respectively.
DKK-1 (Adipo Bioscience, USA, Cat No: SK00312-01): The
sensitivity of the assay was 62.5 pg/mL. The intra-assay and
inter-assay coefficients of variation were 4-6% and 8-10%,
respectively.
BMP-7 (Adipo Bioscience, USA, Cat No: SK00019-01): The
sensitivity of the assay was 31.25 pg/mL. The intra-assay
and inter-assay coefficients of variation were 4-6% and
8-10%, respectively.
Sclerostin (Biomedica Gruppe, Vienna, Austria, Cat. No.:
BI-20492): The sensitivity of the assay was 62.5 pg/mL. The
intra-assay and inter-assay coefficients of variation were
4-6% and 8-10%, respectively.
Fetuin-A (Assay Pro, USA, Cat No:EG3501-1): The
minimum detectable dose of alpha-2-HS-Glycoprotein is
,3 ng/ml. The intra-assay and inter-assay coefficients of
variation were 5.0% and 7.0%, respectively.
Statistical analysis
The statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS), version 16.0
(Chicago, IL, USA). The Kolmogorov–Smirnov normality
test was used to determine the distribution pattern of
the variables. Most of the parameters, including fetuin-A,
DKK-1, sclerostin and hs-CRP, showed a normal distribu-
tion and we used parametric tests for the statistical
analysis. Data were expressed as the mean ¡ standard
deviation for continuous variables or as percentages of the
total for categorical variables. Student’s t-test was used for
comparisons between two groups of continuous variables.
The Pearson x2 or Fisher’s exact test was performed to
compare categorical variables. The relationships between
different variables were analyzed by the Pearson correla-
tion test. Binary logistical regression analysis was used
to identify the factors associated with the presence of
syndesmophytes. A one-way ANOVA was used to test
for differences among the three group means (patients
with and without syndesmophytes and healthy controls).
Kappa statistics were used to assess the agreement of the
observers. A double-tailed p value of ,0.05 was considered
statistically significant.
& RESULTS
There were 94 patients (49 without syndesmophyte, 67.3%
male [M], 40.7¡8.7 years; 45 with syndesmophyte, 71.1% M,
43.9¡9.9 years) and 68 healthy control subjects (44.2¡10.6
years and 70.6% M) in the study group. The age, sex
distributions, number of patients with HT, DM and smoking
status were similar between the three groups (p.0.05). The
demographical and clinical characteristics of the groups are
summarized in Table 1.
Comparison of the syndesmophyte-positive and
-negative patients and healthy control groups
Fetuin-A was significantly higher in the AS patients with
syndesmophytes compared with patients without syndes-
mophytes and healthy controls (Figure 1, p,0.05; 1.16¡0.13,
1.05¡0.09 and 1.08¡0.13 mg/ml, respectively). The con-
centrations of DKK-1 were significantly higher in both the
syndesmophyte-positive and -negative patient groups com-
pared with controls (p,0.05; 1911¡1344, 1727¡1083 and
672¡592 pg/ml, respectively). The BMP-7 levels were
significantly down-regulated in the patients with and
without syndesmophytes compared with healthy controls
(p,0.05; 9.4¡15.6, 10.7¡16.4 and 75.8¡110 pg/ml, respec-
tively). Both IL-6 and hs-CRP were significantly higher in
the patient group than in controls (p,0.05, Table 2). By
contrast, the sclerostin levels were similar between the
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groups (p.0.05). Post hoc comparisons between the groups
for each biomarker are summarized in Table 2.
Comparison of the syndesmophyte-positive and
-negative patients
The disease duration and BASFI and BASDAI values
were comparable between the AS patients with and
without syndesmophytes (p.0.05); however, the BASMI
values were significantly lower in patients with syndesmo-
phytes (p,0.0001, 3.2¡1.5 vs. 4.9¡1.9). The proportion
of patients receiving biological agents, non-steroid anti-
inflammatory drugs (NSAIDs) and sulfasalazine (SSZ)
were not different between the patients with and without
syndesmophytes (p.0.05). The percentages of patients
receiving NSAIDs on a continuous or on-demand basis
were also similar between the two groups (p.0.05). The
fetuin-A levels were significantly higher in patients with
syndesmophytes (p= 0.01; 1.16¡0.13 vs. 1.05¡0.09 mg/ml,
respectively) than in those without. The levels of other
soluble biomarkers, including DKK-1, sclerostin, BMP-7,
IL-6 and hs-CRP, were not different between the two
groups (p.0.05).
Correlation analysis
Correlation analysis showed that the presence of syndes-
mophytes was significantly and positively correlated with
the BASMI and fetuin-A levels (p,0.05, r = 0.5 and 0.3,
respectively). However, there were no correlations between
the presence of syndesmophytes and IL-6, hs-CRP, DKK-1,
sclerostin, and BMP-7 levels (p.0.05). Additionally, no
correlation was observed for the disease duration, BASDAI,
BASFI, anti-tumor necrosis factor alpha (TNF-a) or NSAID
therapy, smoking status, presence of HT or DM.
Correlations with other variables are given in Table 3.
Regression analysis
We performed binary logistic regression analysis to
identify the factors that were the independent predictors
of syndesmophytes. In the model, we included the age, sex,
disease duration, BASDAI, BASFI, BASMI, hs-CRP, IL-6,
DKK-1, BMP-7 and fetuin-A. When all predictor variables
are considered together, they significantly predict syndes-
mophytes, X2 = 46.42, df = 12, n = 80 and p,0.001. In the
model, increased fetuin-A (odds ratio [OR], and 95%
confidence interval [CI] = 422.7, and 4.8-37201, respectively),
Table 1 - Demographic and clinical characteristics of the study group.
AS patients Controls, n = 68 p
Syndesmophyte (+), n = 45 Syndesmophyte (-), n = 49
Age (years) 43.9¡9.9 40.7¡8.7 44.2¡10.6 0.12
Sex (M/F) 32/13 33/16 48/20 0.9
Ever smoked, % 80 71.4 66.1 0.29
Hypertension, % 6.7 2 1.5 0.26
Diabetes, % 2.2 2 0 0.48
Disease duration (years) 15.4¡7.5 14.7¡7.3 0.69
BASFI (0-10) 3.59¡3 2.93¡2.44 0.28
BASDAI (0-10) 3.7¡2.46 4.2¡2.6 0.41
BASMI (0-10) 4.9¡1.9 3.2¡1.5 ,0.0001
Patients treated with biologics, % 31.1 34.7 0.83
NSAIDs use, % 75 87.8 0.18
Patients treated with SSZ, % 22.2 34.7 0.25
Continuous data are presented as the mean¡standard deviation. BASDAI: Bath ankylosing spondylitis disease activity index, BASFI: Bath ankylosing
spondylitis functional index, BASMI: Bath ankylosing spondylitis metrology index, NSAIDs: non-steroid anti-inflammatory drugs and SSZ: sulfasalazine.
Figure 1 - Box plot of the mean fetuin-A levels for two groups of patients (with and without syndesmophytes) and healthy controls.
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BASMI (OR, and 95%CI= 3.2, and 1.8-5.9, respectively) and
BASDAI (OR, and 95%CI= 0.64, and 0.46-0.89, respectively)
significantly and independently predicted syndesmophytes.
& DISCUSSION
In this study, we detected higher fetuin-A levels in AS
patients with syndesmophytes compared with patients
without syndesmophytes and healthy controls, which was
the primary focus of the study. Moreover, fetuin-A was an
independent, significant predictor of the presence of
syndesmophytes. The results of this study are inconsistent
with our previous study, which showed significantly higher
levels of fetuin-A in 45 AS patients compared with 29
healthy subjects (4). However, that study did not include a
radiographic assessment. In the current study, we excluded
subjects with renal failure and patients receiving corticos-
teroids to avoid the negative effect of these variables on the
molecule (12). The age, sex distributions and disease
durations as well as the prevalence of hypertension and
diabetes mellitus, which may affect the serum fetuin-A
levels (13), were similar in the two patient groups. Fetuin-A
has also been evaluated in several other inflammatory
rheumatic diseases, including rheumatoid arthritis, which
revealed decreased levels of this molecule in this group of
patients compared with healthy subjects (12). This finding
may only be a reflection of the negative acute-phase reactant
nature of fetuin-A (14).
New bone formation that develops in both the upper and
lower endplates of the vertebra is a hallmark feature of AS.
It becomes visible on radiographs as a syndesmophyte,
which is the most typical finding of structural damage
(1,15). Bony spur formation and ankylosis may limit the
range of motion of the spine and eventually compromise
function and cause deformity. Therefore, significant
research has focused on understanding the cellular and
molecular mechanisms of bone formation in AS (3).
Fetuin-A, formerly known as a2-Heremans-Schmid
glycoprotein, is a molecule that is mainly synthesized in
the liver (12). It is abundantly found in calcified tissues,
including bone and ectopic calcified lesions (12,16) and
shows high affinity for calcium phosphate minerals and
related compounds (17). Animal studies have shown
that fetuin-A-deficient mice display calcification of various
tissues, suggesting that it may act as an ectopic calcifica-
tion inhibitor (12,17). However, its abundant presence in
bone suggests it may promote bone mineralization.
Increased serum fetuin-A levels have been reported in
fetal calves compared with adult cows, which may reflect
a higher rate of bone mineralization in early fetal life
(18,19). Moreover, higher fetuin-A levels were associated
with higher bone mineral density among well-functioning
community-dwelling elderly women (20). In line with
these observations, fetuin-A was demonstrated as both
necessary and sufficient for calcification of the type I
collagen fibril (21).
Table 2 - Laboratory characteristics of the study group.
AS patients Controls n= 68 p p1 p2 p3
Syndesmophyte (+) n = 45 Syndesmophyte (-) n = 49
Fetuin-A (mg/ml) 1.16¡0.13 1.05¡0.09 1.08¡0.13 ,0.0001 ,0.0001 0.004 0.3
DKK-1 (pg/ml) 1911¡1344 1727¡1083 672¡592 ,0.0001 0.64 ,0.0001 ,0.0001
Sclerostin (pg/ml) 151¡128 126¡99 151¡158 0.6
BMP-7 (pg/ml) 9.4¡15.6 10.7¡16.4 75.8¡110 ,0.0001 0.99 ,0.0001 ,0.0001
hs-CRP (mg/ml) 8.9¡6.4 10.6¡7 3.3¡2.8 ,0.0001 0.32 ,0.0001 ,0.0001
IL-6 (pg/ml) 3.27¡0.89 3.47¡1.26 3.04¡0.27 0.03 0.48 0.37 0.02
Continuous data are presented as the mean¡standard deviation. DKK-1: dickkopf-1, BMP-7: bone morphogenetic protein-7, hs-CRP: high-sensitivity
C-reactive protein.
p represents the significance for the three group comparisons. Post hoc group comparisons were defined as follows: p1: syndesmophyte-positive vs.
syndesmophyte-negative patients, p2: syndesmophyte-positive patients vs. healthy controls, and p3: syndesmophyte-negative patients vs. healthy
controls.
Table 3 - Correlation coefficients of the clinical and laboratory data.
Syn Age Dd hs-CRP IL-6 Fetuin-A DKK-1 Sclerostin BMP-7 Smoking BASFI BASDAI BASMI
Syn 0.3 0.5
Age 0.4
Dx 0.4 0.3
hs-CRP 0.6 0.3 -0.2 0.3 0.4
IL-6 0.6 0.2
Fetuin-A 0.3
DKK-1 0.3 0.2
Sclerostin 0.2
BMP-7 -0.2
Smoking
BASFI 0.3 0.7 0.5
BASDAI 0.4 0.7 0.3
BASMI 0.5 0.3 0.5 0.3
The values indicate the correlation coefficients. Note that empty cells indicate that there was no significance between the variables. Syn: syndesmophytes,
Dd: disease duration, DKK-1: dickkopf-1, BMP-7: bone morphogenetic protein-7, hs-CRP: high-sensitivity C-reactive protein, BASFI: Bath ankylosing
spondylitis functional index, BASDAI: Bath ankylosing spondylitis disease activity index and BASMI: Bath ankylosing spondylitis metrology index.
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DKK-1 is a molecule that has an inhibitory effect on
osteoblastic activity by suppressing the WNT signaling
pathway. It has been suggested that decreased or dysfunc-
tional DKK-1 is associated with increased osteoblastic
activity, inducing or promoting syndesmophytes (22,23).
Several reports investigated the DKK-1 levels in AS (24-29).
However, these studies are inconsistent in their findings.
Some reported increased concentrations of DKK-1 in AS
(26,27), whereas others did not find any differences or
showed decreased levels of the molecule (28,29). In the
current study, we revealed that both the patients with and
without syndesmophytes had significantly higher levels of
DKK-1 compared with healthy subjects. Sclerostin is a
natural inhibitor of the WNT pathway (30). Similar to DKK-
1, there are also contradictory results regarding the
association of sclerostin and AS (25,29,31,32). In our study,
we found that the sclerostin concentrations were not
different between the study groups. BMPs are members of
the transforming growth factor beta superfamily that play a
crucial role in skeletal and joint morphogenesis (33). They
are reported to play a role in pathologic new bone
formation, especially BMP-7 (7). Because of the association
of BMPs with new formation, several reports studied
different BMPs in AS (7,34-36). In the current study, we
showed that the BMP-7 concentrations were significantly
lower in the total AS group compared with healthy controls.
However, in the subgroup analysis, the BMP-7 levels were
not different between the patients with and without
syndesmophytes. The main limitations of our study are its
cross-sectional design and the lack of information on the
HLAB27 status of the patients.
In conclusion, higher fetuin-A levels in AS patients with
syndesmophytes than in those without syndesmophytes
and in healthy controls suggest a role for this molecule in
the pathogenesis of bony proliferation in AS, which needs to
be explored in prospective studies.
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